Viibryd (大うつ病性障害)：医薬品市場予測及び分析（～2023）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 11
3.2 Classification 13
3.3 Symptoms and Subtypes of Major Depressive Disorder 15
3.4 Prognosis 16
3.5 Quality of Life 16
4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Diagnosis 17
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 18
4.1.3 Clinical Practice 21
5 Competitive Assessment 26
5.1 Overview 26
6 Viibryd (Vilazodone) 28
6.1 Overview 28
6.2 Efficacy 29
6.3 Safety 30
6.4 SWOT Analysis 31
6.5 Forecast 31
7 Appendix 33
7.1 Bibliography 33
7.2 Abbreviations 35
7.3 Methodology 37
7.4 Forecasting Methodology 37
7.4.1 Diagnosed MDD Patients 37
7.4.2 Percent of Drug-Treated Patients 37
7.4.3 General Pricing Assumptions 38
7.4.4 Individual Drug Assumptions 38
7.4.5 Generic Erosion 39
7.5 Physicians and Specialists Included in this Study 40
7.6 About the Authors 42
7.6.1 Analyst 42
7.6.2 Therapy Area Directors 42
7.6.3 Global Head of Healthcare 43
7.7 About GlobalData 44
7.8 Disclaimer 44